Small molecule · Inhibitor of cap binding complex (CBC) 80/20 · developed by Abivax
Obefazimod is an orally available small molecule that binds the cap binding complex (CBC) 80/20 at the 5'-end of pre-mRNA transcripts. It inhibits HIV-1 replication by preventing Rev-mediated export of unspliced viral transcripts and upregulates the anti-inflammatory microRNA miR-124, reducing production of inflammatory mediators including IL-6, TNF-alpha, and CCL2. It is studied in HIV infection, Crohn disease, ulcerative colitis, and rheumatoid arthritis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05535946 | Phase 3 | Ulcerative Colitis | Active not recruiting | ABVX |
| NCT06456593 | Phase 2 | Moderately to Severely Active Crohn Disease | Recruiting | ABVX |
| NCT03760003 | Phase 2 | Ulcerative Colitis | Completed | ABVX |
| NCT03813199 | Phase 2 | Rheumatoid Arthritis | Completed | ABVX |
| NCT02990325 | Phase 1/2 | HIV Infections | Completed | ABVX |
| NCT07453784 | Phase 1 | Healthy | Recruiting | ABVX |
| NCT02731885 | Phase 1 | Healthy Volunteers | Completed | ABVX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
HealthyModerately to Severely Active Crohn DiseaseHealth VolunteersHealthy VolunteersHIV InfectionsRheumatoid ArthritisUlcerative Colitis
Updated Oct 3, 2026. Something wrong or missing? Report it on the ABVX page.
See ABVX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ABVX catalysts and pipeline →